APLS Q1 2023 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$45M+211.8% YoY

Gross Profit

$37M82.6% margin

Operating Income

-$175M-390.4% margin

Net Income

-$178M-396.4% margin

EPS (Diluted)

$-1.56

QoQ Revenue Growth

+97.9%

Cash Flow

Operating Cash Flow

-$178M

Free Cash Flow

-$178M

Stock-Based Comp.

$29M

Balance Sheet

Total Assets

$979M

Total Liabilities

$567M

Stockholders' Equity

$412M

Cash & Equivalents

$765M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$45M	$14M	+211.8%
Gross Profit	$37M	$13M	+182.0%
Operating Income	-$175M	-$129M	-35.7%
Net Income	-$178M	-$139M	-28.0%

Revenue Segments

Product

$39M87%

Licensing And Other Revenue

$6M13%